Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbreviated FDA Inspections Outlined In Draft CPG For Auditing Program

This article was originally published in The Gray Sheet

Executive Summary

Medical device facilities should receive a comprehensive quality system inspection every six years "as district resources permit" with "abbreviated" inspections in between, according to a draft FDA compliance program guidance (CPG) on auditing device manufacturers.

You may also be interested in...



"Minor" Infractions Will Not Trigger Warning Letter Under Final CPG

FDA inspections that uncover "minor nonconformities" with a company's quality system regulations (QSRs) will not draw regulatory follow-up action under the agency's soon-to-be-published final compliance program guidance (CPG) for medical device audits.

"Minor" Infractions Will Not Trigger Warning Letter Under Final CPG

FDA inspections that uncover "minor nonconformities" with a company's quality system regulations (QSRs) will not draw regulatory follow-up action under the agency's soon-to-be-published final compliance program guidance (CPG) for medical device audits.

CDRH QSIT Team Considers Third-Party Audit Option To Level 1 Inspections

Firms with a good compliance history may be eligible to submit third-party auditing certifications in lieu of biennial FDA inspections, according to a proposal being drafted for consideration by the Center for Devices and Radiological Health's quality systems inspection technique (QSIT) reengineering team.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel